MX2007004423A - Calcio de rosuvastatina con bajo contenido de sal. - Google Patents

Calcio de rosuvastatina con bajo contenido de sal.

Info

Publication number
MX2007004423A
MX2007004423A MX2007004423A MX2007004423A MX2007004423A MX 2007004423 A MX2007004423 A MX 2007004423A MX 2007004423 A MX2007004423 A MX 2007004423A MX 2007004423 A MX2007004423 A MX 2007004423A MX 2007004423 A MX2007004423 A MX 2007004423A
Authority
MX
Mexico
Prior art keywords
rosuvastatin calcium
low salt
salt content
rosuvastatin
calcium
Prior art date
Application number
MX2007004423A
Other languages
English (en)
Inventor
Valerie Niddam-Hildesheim
Shalom Shabat
Dalia Maidan-Hanoch
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of MX2007004423A publication Critical patent/MX2007004423A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporciona calcio de rosuvastatina con un contenido de subproducto de sal bajo y procesos para la preparacion de dicho calcio de rosuvastatina.
MX2007004423A 2005-08-16 2006-08-16 Calcio de rosuvastatina con bajo contenido de sal. MX2007004423A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70906505P 2005-08-16 2005-08-16
PCT/US2006/032165 WO2007022366A2 (en) 2005-08-16 2006-08-16 Rosuvastatin calcium with a low salt by-product content

Publications (1)

Publication Number Publication Date
MX2007004423A true MX2007004423A (es) 2007-06-14

Family

ID=37507612

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007004423A MX2007004423A (es) 2005-08-16 2006-08-16 Calcio de rosuvastatina con bajo contenido de sal.

Country Status (10)

Country Link
US (3) US20070099994A1 (es)
EP (1) EP1919880A2 (es)
JP (1) JP2008513520A (es)
KR (2) KR20090108671A (es)
BR (1) BRPI0605918A2 (es)
CA (1) CA2619867A1 (es)
IL (1) IL188648A0 (es)
MX (1) MX2007004423A (es)
TW (1) TW200800918A (es)
WO (1) WO2007022366A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007004423A (es) * 2005-08-16 2007-06-14 Teva Pharma Calcio de rosuvastatina con bajo contenido de sal.
US8318933B2 (en) * 2006-10-31 2012-11-27 Aurobindo Pharma Ltd Process for preparing rosuvastatin calcium
ATE553098T1 (de) * 2007-02-08 2012-04-15 Aurobindo Pharma Ltd Verfahren zur herstellung von rosuvastatin- calcium
PL2172471T3 (pl) * 2007-04-18 2013-08-30 Teva Pharma Sposób otrzymywania produktów pośrednich inhibitorów reduktazy HMG-CoA
EP2178846A1 (en) * 2007-07-12 2010-04-28 Teva Pharmaceutical Industries Ltd. Rosuvastatin intermediates and their preparation
EP2699552A1 (en) 2011-04-18 2014-02-26 Basf Se Multicomponent crystalline system of rosuvastatin calcium salt and vanillin
KR102059995B1 (ko) 2017-09-20 2019-12-27 주식회사 큐브인스트루먼트 저온 멸균 장치를 이용한 멸균 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2732309A (en) * 1952-08-28 1956-01-24 Process for the production of cold
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US6777552B2 (en) * 2001-08-16 2004-08-17 Teva Pharmaceutical Industries, Ltd. Processes for preparing calcium salt forms of statins
US20050222415A1 (en) * 2002-05-21 2005-10-06 Yatendra Kumar Process for the preparation of rosuvastatin
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
GB0312896D0 (en) * 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
WO2005023778A2 (en) * 2003-08-28 2005-03-17 Teva Pharmaceutical Industries Ltd. Process for preparation of rosuvastatin calcium
US20070191318A1 (en) * 2003-10-22 2007-08-16 Yatendra Kumar Process for the preparation of amorphous rosuvastatin calcium
WO2005054207A1 (en) 2003-12-04 2005-06-16 Glenmark Pharmaceuticals Limited Process for the preparation of pyrimidine derivatives
MX2007004423A (es) * 2005-08-16 2007-06-14 Teva Pharma Calcio de rosuvastatina con bajo contenido de sal.

Also Published As

Publication number Publication date
EP1919880A2 (en) 2008-05-14
BRPI0605918A2 (pt) 2009-05-26
JP2008513520A (ja) 2008-05-01
KR20070065359A (ko) 2007-06-22
US20090215806A1 (en) 2009-08-27
KR20090108671A (ko) 2009-10-15
WO2007022366A3 (en) 2007-05-31
US20090240054A1 (en) 2009-09-24
WO2007022366A2 (en) 2007-02-22
TW200800918A (en) 2008-01-01
CA2619867A1 (en) 2007-02-22
IL188648A0 (en) 2008-08-07
US20070099994A1 (en) 2007-05-03
WO2007022366A8 (en) 2007-12-06
WO2007022366B1 (en) 2007-07-12

Similar Documents

Publication Publication Date Title
MY147435A (en) Process for the production of atorvastatin calcium in amorphous form
MX2007004423A (es) Calcio de rosuvastatina con bajo contenido de sal.
TW200617019A (en) A process for the preparation of 7α-alkylated 19-norsteroids
TW200745138A (en) Process for stabilising thiophene derivatives
MX2007005295A (es) Nuevos catalizadores de trimerizacion a partir de sales estericamente impedidas.
PL1915349T5 (pl) Sposób wytwarzania czystej bezpostaciowej rozuwastatyny wapniowej
HK1116996A1 (en) Low ph aerated products
TW200715632A (en) Inorganic compounds
MX2007000224A (es) Uso de 2-tio-3,5-diciano-4-fenil-6-aminopiridinas sustituidas en el tratamiento de nauseas y vomitos.
EP2032715A4 (en) METHODS AND MATERIALS FOR THE PREPARATION OF SIMVASTATIN AND ITS COMPOUNDS
IL185031A0 (en) Method for the preparation of pregabalin and salts thereof
TW200732337A (en) Organic compounds
PL1888514T3 (pl) Sole podstawionych estrów kwasu alofanowego i ich zastosowanie w środkach leczniczych
TW200806221A (en) Method of relating different products by a common feature
TW200728310A (en) Process for the preparation of ferri-succinylcasein
TW200730521A (en) Triazine compounds having amino-and carboxyl-containing substituents
TW200637832A (en) Process for preparing amorphous valsartan
MX2010002506A (es) Compuestos de nicotinamida sustituidos y uso de estos en medicamentos.
MX2010005192A (es) Bebida que comprende arginina.
MX2007004427A (es) Intermedio de rosuvastatina cristalina.
TW200640376A (en) Reduction of digestibility of phosphorus
TW200626079A (en) Method of storing fragrant component
SG143133A1 (en) Continuous processes for the production of ethoxylates
UA91565C2 (en) Thiazols, use of thiazols as fungicides
UA35617U (en) Fungicidal composition

Legal Events

Date Code Title Description
FA Abandonment or withdrawal